{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["COVID-19", "Coronavirus", "Docking", "Drug repurposing", "SARS-CoV-2"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "32561274", "DateCompleted": {"Year": "2020", "Month": "09", "Day": "24"}, "DateRevised": {"Year": "2021", "Month": "01", "Day": "10"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "06", "Day": "16"}], "Language": ["eng"], "ELocationID": ["10.1016/j.jiph.2020.06.016", "S1876-0341(20)30526-8"], "Journal": {"ISSN": "1876-035X", "JournalIssue": {"Volume": "13", "Issue": "9", "PubDate": {"Year": "2020", "Month": "Sep"}}, "Title": "Journal of infection and public health", "ISOAbbreviation": "J Infect Public Health"}, "ArticleTitle": "In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.", "Pagination": {"StartPage": "1210", "EndPage": "1223", "MedlinePgn": "1210-1223"}, "Abstract": {"AbstractText": ["The rapidly enlarging COVID-19 pandemic caused by the novel SARS-corona virus-2 is a global public health emergency of an unprecedented level. Unfortunately no treatment therapy or vaccine is yet available to counter the SARS-CoV-2 infection, which substantiates the need to expand research efforts in this direction. The indispensable function of the main protease in virus replication makes this enzyme a promising target for inhibitors screening and drug discovery to treat novel coronavirus infection. The recently concluded \u03b1-ketoamide ligand-bound X-ray crystal structure of SARS-CoV-2 M<sup>pro</sup> (PDB ID: 6Y2F) from Zhang et al. has revealed the potential inhibitor binding mechanism and the molecular determinants responsible for substrate binding.", "For the study, we have targeted the SARS-CoV-2 M<sup>pro</sup> for the screening of FDA approved antiviral drugs and carried out molecular docking based virtual screening. Further molecular dynamic simulation studies of the top three selected drugs carried out to investigated for their binding affinity and stability in the SARS-CoV-2 M<sup>pro</sup> active site. The phylogenetic analysis was also performed to know the relatedness between the SARS-CoV-2 genomes isolated from different countries.", "The phylogenetic analysis of the SARS-CoV-2 genome reveals that the virus is closely related to the Bat-SL-CoV and does not exhibit any divergence at the genomic level. Molecular docking studies revealed that among the 77 drugs, screened top ten drugs shows good binding affinities, whereas the top three drugs: Lopinavir-Ritonavir, Tipranavir, and Raltegravir were undergone for molecular dynamics simulation studies for their conformational stability in the active site of the SARS-CoV-2 M<sup>pro</sup> protein.", "In the present study among the library of FDA approved antiviral drugs, the top three inhibitors Lopinavir-Ritonavir, Tipranavir, and Raltegravir show the best molecular interaction with the main protease of SARS-CoV-2. However, the in-vitro efficacy of the drug molecules screened in this study further needs to be corroborated by carrying out a biochemical and structural investigation."], "CopyrightInformation": "Copyright \u00a9 2020. Published by Elsevier Ltd."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Metabolic & Structural Biology, CSIR-Central Institute of Medicinal & Aromatic Plants, Lucknow 226015, India; Department of Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany. Electronic address: kumar.yogesh601@gmail.com."}], "LastName": "Kumar", "ForeName": "Yogesh", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry, Molecular Biology & Biophysics, University of Minnesota, Minneapolis, MN 55455, USA. Electronic address: hsingh@umn.edu."}], "LastName": "Singh", "ForeName": "Harvijay", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Botany, Bioinformatics & Climate Impacts Management, University School of Sciences, Gujarat University, Navrangpur, Ahmedabad 280009, Gujarat, India."}], "LastName": "Patel", "ForeName": "Chirag N", "Initials": "CN"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "J Infect Public Health", "NlmUniqueID": "101487384", "ISSNLinking": "1876-0341"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antiviral Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Drug Combinations"}, {"RegistryNumber": "0", "NameOfSubstance": "Protease Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyridines"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyrones"}, {"RegistryNumber": "0", "NameOfSubstance": "Sulfonamides"}, {"RegistryNumber": "0", "NameOfSubstance": "Viral Nonstructural Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "lopinavir-ritonavir drug combination"}, {"RegistryNumber": "2494G1JF75", "NameOfSubstance": "Lopinavir"}, {"RegistryNumber": "43Y000U234", "NameOfSubstance": "Raltegravir Potassium"}, {"RegistryNumber": "EC 3.4.22.-", "NameOfSubstance": "Cysteine Endopeptidases"}, {"RegistryNumber": "EC 3.4.22.28", "NameOfSubstance": "Coronavirus 3C Proteases"}, {"RegistryNumber": "O3J8G9O825", "NameOfSubstance": "Ritonavir"}, {"RegistryNumber": "ZZT404XD09", "NameOfSubstance": "tipranavir"}], "MeshHeadingList": [{"QualifierName": ["chemistry"], "DescriptorName": "Antiviral Agents"}, {"QualifierName": ["enzymology", "genetics"], "DescriptorName": "Betacoronavirus"}, {"QualifierName": [], "DescriptorName": "COVID-19"}, {"QualifierName": [], "DescriptorName": "Coronavirus 3C Proteases"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Coronavirus Infections"}, {"QualifierName": ["chemistry"], "DescriptorName": "Cysteine Endopeptidases"}, {"QualifierName": [], "DescriptorName": "Drug Combinations"}, {"QualifierName": [], "DescriptorName": "Drug Repositioning"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemistry"], "DescriptorName": "Lopinavir"}, {"QualifierName": [], "DescriptorName": "Molecular Conformation"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Molecular Dynamics Simulation"}, {"QualifierName": [], "DescriptorName": "Pandemics"}, {"QualifierName": [], "DescriptorName": "Phylogeny"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Pneumonia, Viral"}, {"QualifierName": ["chemistry"], "DescriptorName": "Protease Inhibitors"}, {"QualifierName": ["chemistry"], "DescriptorName": "Pyridines"}, {"QualifierName": ["chemistry"], "DescriptorName": "Pyrones"}, {"QualifierName": ["chemistry"], "DescriptorName": "Raltegravir Potassium"}, {"QualifierName": ["chemistry"], "DescriptorName": "Ritonavir"}, {"QualifierName": [], "DescriptorName": "SARS-CoV-2"}, {"QualifierName": [], "DescriptorName": "Sulfonamides"}, {"QualifierName": ["antagonists & inhibitors", "chemistry"], "DescriptorName": "Viral Nonstructural Proteins"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Zhu N., Zhang D., Wang W., Li X., Yang B., Song J. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727\u2013733. doi: 10.1056/NEJMoa2001017.", "ArticleIdList": ["10.1056/NEJMoa2001017", "PMC7092803", "31978945"]}, {"Citation": "WHO coronavirus disease (COVID-19) dashboard. n.d. https://covid19.who.int/. [Accessed 15 May 2020]."}, {"Citation": "Hung I.F.-N., Lung K.-C., Tso E.Y.-K., Liu R., Chung T.W.-H., Chu M.-Y. Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;0 doi: 10.1016/S0140-6736(20)31042-4.", "ArticleIdList": ["10.1016/S0140-6736(20)31042-4", "PMC7211500", "32401715"]}, {"Citation": "Reuters; 2020. Gilead to end coronavirus drug trials, adding to access worry \u2014 researchers."}, {"Citation": "Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507\u2013513. doi: 10.1016/S0140-6736(20)30211-7.", "ArticleIdList": ["10.1016/S0140-6736(20)30211-7", "PMC7135076", "32007143"]}, {"Citation": "Cui J., Li F., Shi Z.-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181\u2013192. doi: 10.1038/s41579-018-0118-9.", "ArticleIdList": ["10.1038/s41579-018-0118-9", "PMC7097006", "30531947"]}, {"Citation": "CDC Coronavirus disease 2019 (COVID-19) Cent Dis Control Prev. 2020 https://www.cdc.gov/coronavirus/2019-ncov/index.html [Accessed 14 May 2020]"}, {"Citation": "Hui D.S., Azhar E.I., Madani T.A., Ntoumi F., Kock R., Dar O. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health \u2014 the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264\u2013266. doi: 10.1016/j.ijid.2020.01.009.", "ArticleIdList": ["10.1016/j.ijid.2020.01.009", "PMC7128332", "31953166"]}, {"Citation": "Zhou Y., Hou Y., Shen J., Huang Y., Martin W., Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020;6:1\u201318. doi: 10.1038/s41421-020-0153-3.", "ArticleIdList": ["10.1038/s41421-020-0153-3", "PMC7073332", "32194980"]}, {"Citation": "Woo P.C.Y., Huang Y., Lau S.K.P., Yuen K.-Y. Coronavirus genomics and bioinformatics analysis. Viruses. 2010;2:1804\u20131820. doi: 10.3390/v2081803.", "ArticleIdList": ["10.3390/v2081803", "PMC3185738", "21994708"]}, {"Citation": "Hussain S., Pan J., Chen Y., Yang Y., Xu J., Peng Y. Identification of novel subgenomic RNAs and noncanonical transcription initiation signals of severe acute respiratory syndrome coronavirus. J Virol. 2005;79:5288\u20135295. doi: 10.1128/JVI.79.9.5288-5295.2005.", "ArticleIdList": ["10.1128/JVI.79.9.5288-5295.2005", "PMC1082772", "15827143"]}, {"Citation": "Wong S.K., Li W., Moore M.J., Choe H., Farzan M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem. 2004;279:3197\u20133201. doi: 10.1074/jbc.C300520200.", "ArticleIdList": ["10.1074/jbc.C300520200", "PMC7982343", "14670965"]}, {"Citation": "Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J. 2014;281:4085\u20134096. doi: 10.1111/febs.12936.", "ArticleIdList": ["10.1111/febs.12936", "PMC7163996", "25039866"]}, {"Citation": "Yang Y.M., Gupta S.K., Kim K.J., Powers B.E., Cerqueira A., Wainger B.J. A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell. 2013;12:713\u2013726. doi: 10.1016/j.stem.2013.04.003.", "ArticleIdList": ["10.1016/j.stem.2013.04.003", "PMC3707511", "23602540"]}, {"Citation": "Sun W., Sanderson P.E., Zheng W. Drug combination therapy increases successful drug repositioning. Drug Discov Today. 2016;21:1189\u20131195. doi: 10.1016/j.drudis.2016.05.015.", "ArticleIdList": ["10.1016/j.drudis.2016.05.015", "PMC4907866", "27240777"]}, {"Citation": "Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors. Science. 2020;368:409\u2013412. doi: 10.1126/science.abb3405.", "ArticleIdList": ["10.1126/science.abb3405", "PMC7164518", "32198291"]}, {"Citation": "Kouznetsova J., Sun W., Mart\u00ednez-Romero C., Tawa G., Shinn P., Chen C.Z. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg Microbes Infect. 2014;3:1\u20137. doi: 10.1038/emi.2014.88.", "ArticleIdList": ["10.1038/emi.2014.88", "PMC4317638", "26038505"]}, {"Citation": "He S., Lin B., Chu V., Hu Z., Hu X., Xiao J. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Sci Transl Med. 2015;7 doi: 10.1126/scitranslmed.3010286.", "ArticleIdList": ["10.1126/scitranslmed.3010286", "PMC6420960", "25855495"]}, {"Citation": "Barrows N.J., Campos R.K., Powell S.T., Prasanth K.R., Schott-Lerner G., Soto-Acosta R. A screen of FDA-approved drugs for inhibitors of zika virus infection. Cell Host Microbe. 2016;20:259\u2013270. doi: 10.1016/j.chom.2016.07.004.", "ArticleIdList": ["10.1016/j.chom.2016.07.004", "PMC4993926", "27476412"]}, {"Citation": "Fan H.-H., Wang L.-Q., Liu W.-L., An X.-P., Liu Z.-D., He X.-Q. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model. Chin Med J (Engl) 2020;133:1051\u20131056. doi: 10.1097/CM9.0000000000000797.", "ArticleIdList": ["10.1097/CM9.0000000000000797", "PMC7147283", "32149769"]}, {"Citation": "Cao B., Wang Y., Wen D., Liu W., Wang J., Fan G. A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787\u20131799. doi: 10.1056/NEJMoa2001282.", "ArticleIdList": ["10.1056/NEJMoa2001282", "PMC7121492", "32187464"]}, {"Citation": "Yang H., Yang M., Ding Y., Liu Y., Lou Z., Zhou Z. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci U S A. 2003;100:13190\u201313195. doi: 10.1073/pnas.1835675100.", "ArticleIdList": ["10.1073/pnas.1835675100", "PMC263746", "14585926"]}, {"Citation": "Tamura K., Stecher G., Peterson D., Filipski A., Kumar S. MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol. 2013;30:2725\u20132729. doi: 10.1093/molbev/mst197.", "ArticleIdList": ["10.1093/molbev/mst197", "PMC3840312", "24132122"]}, {"Citation": "PubChem. PubChem. n.d. https://pubchem.ncbi.nlm.nih.gov/. [Accessed 15 May 2020]."}, {"Citation": "Trott O., Olson A.J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem. 2010;31:455\u2013461. doi: 10.1002/jcc.21334.", "ArticleIdList": ["10.1002/jcc.21334", "PMC3041641", "19499576"]}, {"Citation": "Laskowski R.A., Swindells M.B. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model. 2011;51:2778\u20132786. doi: 10.1021/ci200227u.", "ArticleIdList": ["10.1021/ci200227u", "21919503"]}, {"Citation": "PyMOL | pymol.org. n.d. https://pymol.org/2/. [Accessed 15 May 2020]."}, {"Citation": "Krieger E., Vriend G. New ways to boost molecular dynamics simulations. J Comput Chem. 2015;36:996\u20131007. doi: 10.1002/jcc.23899.", "ArticleIdList": ["10.1002/jcc.23899", "PMC6680170", "25824339"]}, {"Citation": "Krieger E., Darden T., Nabuurs S.B., Finkelstein A., Vriend G. Making optimal use of empirical energy functions: force-field parameterization in crystal space. Proteins. 2004;57:678\u2013683. doi: 10.1002/prot.20251.", "ArticleIdList": ["10.1002/prot.20251", "15390263"]}, {"Citation": "Desai V.H., Kumar S.P., Pandya H.A., Solanki H.A. Receptor-guided de novo design of dengue envelope protein inhibitors. Appl Biochem Biotechnol. 2015;177:861\u2013878. doi: 10.1007/s12010-015-1784-y.", "ArticleIdList": ["10.1007/s12010-015-1784-y", "26299376"]}, {"Citation": "Kiemer L., Lund O., Brunak S., Blom N. Coronavirus 3CLproproteinase cleavage sites: possible relevance to SARS virus pathology. BMC Bioinformatics. 2004;5 doi: 10.1186/1471-2105-5-72.", "ArticleIdList": ["10.1186/1471-2105-5-72", "PMC442122", "15180906"]}, {"Citation": "Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 2003;300:1763\u20131767. doi: 10.1126/science.1085658.", "ArticleIdList": ["10.1126/science.1085658", "12746549"]}, {"Citation": "De Luca A., Pezzotti P., Boucher C., D\u00f6ring M., Incardona F., Kaiser R. Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: a European survey. PLoS One. 2019;14 doi: 10.1371/journal.pone.0225381.", "ArticleIdList": ["10.1371/journal.pone.0225381", "PMC6874206", "31751385"]}, {"Citation": "Foolad F., Aitken S.L., Chemaly R.F. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients. Expert Rev Clin Pharmacol. 2018;11:931\u2013941. doi: 10.1080/17512433.2018.1500897.", "ArticleIdList": ["10.1080/17512433.2018.1500897", "30004790"]}, {"Citation": "Hayden F.G., Sugaya N., Hirotsu N., Lee N., de Jong M.D., Hurt A.C. Baloxavir Marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379:913\u2013923. doi: 10.1056/NEJMoa1716197.", "ArticleIdList": ["10.1056/NEJMoa1716197", "30184455"]}, {"Citation": "Agarwal K., Brunetto M., Seto W.K., Lim Y.-S., Fung S., Marcellin P. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68:672\u2013681. doi: 10.1016/j.jhep.2017.11.039.", "ArticleIdList": ["10.1016/j.jhep.2017.11.039", "29756595"]}, {"Citation": "Blair H.A. Dolutegravir/rilpivirine: a review in HIV-1 infection. Drugs. 2018;78:1741\u20131750. doi: 10.1007/s40265-018-1005-4.", "ArticleIdList": ["10.1007/s40265-018-1005-4", "30406902"]}, {"Citation": "Yamamoto N., Yang R., Yoshinaka Y., Amari S., Nakano T., Cinatl J. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun. 2004;318:719\u2013725. doi: 10.1016/j.bbrc.2004.04.083.", "ArticleIdList": ["10.1016/j.bbrc.2004.04.083", "PMC7111005", "15144898"]}, {"Citation": "Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors. Science. 2020;368:409\u2013412. doi: 10.1126/science.abb3405.", "ArticleIdList": ["10.1126/science.abb3405", "PMC7164518", "32198291"]}, {"Citation": "Del Puente F., Berruti M., Riccardi N., di Biagio A. Comment on: dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study. J Antimicrob Chemother. 2020 doi: 10.1093/jac/dkaa120.", "ArticleIdList": ["10.1093/jac/dkaa120", "32285104"]}, {"Citation": "Plosker G.L., Figgitt D.P. Tipranavir. Drugs. 2003;63:1611\u20131618. doi: 10.2165/00003495-200363150-00009.", "ArticleIdList": ["10.2165/00003495-200363150-00009", "12887268"]}, {"Citation": "Brites C., N\u00f3brega I., Luz E., Travassos A.G., Lorenzo C., Netto E.M. Raltegravir versus lopinavir/ritonavir for treatment of HIV-infected late-presenting pregnant women. HIV Clin Trials. 2018;19:94\u2013100. doi: 10.1080/15284336.2018.1459343.", "ArticleIdList": ["10.1080/15284336.2018.1459343", "29629852"]}, {"Citation": "WHO Director-General\u2019s remarks at the media briefing on 2019-nCoV on 11 February 2020. n.d. https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. [Accessed 15 May 2020]."}, {"Citation": "Forster P., Forster L., Renfrew C., Forster M. Phylogenetic network analysis of SARS-CoV-2 genomes. Proc Natl Acad Sci U S A. 2020;117:9241\u20139243. doi: 10.1073/pnas.2004999117.", "ArticleIdList": ["10.1073/pnas.2004999117", "PMC7196762", "32269081"]}, {"Citation": "Coronavirus outbreak: top coronavirus drugs and vaccines in development. Clin Trials Arena. 2020 https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/ [Accessed 15 May 2020]"}, {"Citation": "Walls A.C., Park Y.-J., Tortorici M.A., Wall A., McGuire A.T., Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181 doi: 10.1016/j.cell.2020.02.058. 281\u2013292.e6.", "ArticleIdList": ["10.1016/j.cell.2020.02.058", "PMC7102599", "32155444"]}, {"Citation": "Chen Y., Guo Y., Pan Y., Zhao Z.J. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020;525:135\u2013140. doi: 10.1016/j.bbrc.2020.02.071.", "ArticleIdList": ["10.1016/j.bbrc.2020.02.071", "PMC7092824", "32081428"]}, {"Citation": "Doyon L., Tremblay S., Bourgon L., Wardrop E., Cordingley M.G. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res. 2005;68:27\u201335. doi: 10.1016/j.antiviral.2005.07.003.", "ArticleIdList": ["10.1016/j.antiviral.2005.07.003", "16122817"]}, {"Citation": "Larder B.A., Hertogs K., Bloor S., van den Eynde C.H., DeCian W., Wang Y. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS Lond Engl. 2000;14:1943\u20131948. doi: 10.1097/00002030-200009080-00009.", "ArticleIdList": ["10.1097/00002030-200009080-00009", "10997398"]}, {"Citation": "Walmsley S.L., Antela A., Clumeck N., Duiculescu D., Eberhard A., Guti\u00e9rrez F. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807\u20131818. doi: 10.1056/NEJMoa1215541.", "ArticleIdList": ["10.1056/NEJMoa1215541", "24195548"]}, {"Citation": "Cottrell M.L., Hadzic T., Kashuba A.D.M. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 2013;52:981\u2013994. doi: 10.1007/s40262-013-0093-2.", "ArticleIdList": ["10.1007/s40262-013-0093-2", "PMC3805712", "23824675"]}, {"Citation": "Marty F.M., Ljungman P., Chemaly R.F., Maertens J., Dadwal S.S., Duarte R.F. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433\u20132444. doi: 10.1056/NEJMoa1706640.", "ArticleIdList": ["10.1056/NEJMoa1706640", "29211658"]}]}], "History": [{"Year": "2020", "Month": "4", "Day": "2"}, {"Year": "2020", "Month": "6", "Day": "3"}, {"Year": "2020", "Month": "6", "Day": "9"}, {"Year": "2020", "Month": "6", "Day": "21", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "9", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "6", "Day": "21", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "6", "Day": "16"}], "PublicationStatus": "ppublish", "ArticleIdList": ["32561274", "PMC7297718", "10.1016/j.jiph.2020.06.016", "S1876-0341(20)30526-8"]}}]}